WallStreetZenWallStreetZen

NASDAQ: VRTX
Vertex Pharmaceuticals Inc Earnings & Revenue

VRTX past earnings growth

How has VRTX's earnings growth performed historically?
Company
52.02%
Industry
17.88%
Market
36.92%
VRTX's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
VRTX's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
VRTX's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

VRTX past revenue growth

How has VRTX's revenue growth performed historically?
Company
22.03%
Industry
120.36%
Market
161.09%
VRTX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
VRTX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
VRTX's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

VRTX earnings and revenue history

Current Revenue
$8.7B
Current Earnings
$3.3B
Current Profit Margin
37.6%
VRTX's has demonstrated consistent long-term... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

VRTX Return on Equity

Current Company
28.5%
Current Industry
-9.8%
Current Market
-8.3%
VRTX's Return on Equity (28.5%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when VRTX announces earnings.

VRTX Return on Assets

Current Company
21.8%
Current Industry
0.6%
VRTX is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

VRTX Return on Capital Employed

Current Company
28.98%
Current Industry
11.2%
VRTX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

VRTX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
VRTX$8.70B$4.23B$3.27B+30.53%+74.11%
REGN$12.17B$5.26B$4.34B+15.70%+29.16%
MRNA$21.39B$13.68B$11.77B+225.07%+67.35%
BNTX$18.20B$14.35B$10.12B+487.71%+17.07%
ALNY$960.92M-$935.29M-$1.18B+69.13%N/A

Vertex Pharmaceuticals Earnings & Revenue FAQ

What were VRTX's earnings last quarter?

On Invalid Date, Vertex Pharmaceuticals (NASDAQ: VRTX) reported Q3 2022 earnings per share (EPS) of $3.63, up 10% year over year. Total Vertex Pharmaceuticals earnings for the quarter were $930.50 million. In the same quarter last year, Vertex Pharmaceuticals's earnings per share (EPS) was $3.30.

If you're new to stock investing, here's how to buy Vertex Pharmaceuticals stock.

What was VRTX's earnings growth in the past year?

As of Q1 2023, Vertex Pharmaceuticals's earnings has grown 52.02% year over year. This is 34.14 percentage points higher than the US Biotechnology industry earnings growth rate of 17.88%. Vertex Pharmaceuticals's earnings in the past year totalled $3.27 billion.

What was VRTX's revenue last quarter?

On Invalid Date, Vertex Pharmaceuticals (NASDAQ: VRTX) reported Q3 2022 revenue of $2.33 billion up 17.65% year over year. In the same quarter last year, Vertex Pharmaceuticals's revenue was $1.98 billion.

What was VRTX's revenue growth in the past year?

As of Q1 2023, Vertex Pharmaceuticals's revenue has grown 22.03% year over year. This is 98.33 percentage points lower than the US Biotechnology industry revenue growth rate of 120.36%. Vertex Pharmaceuticals's revenue in the past year totalled $8.70 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.